There are currently 117 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.
Effects of Auditory Stimulation on Sleep and Memory in Schizophrenia
NCT04783571
Recruiting
The investigators will test the hypothesis that auditory stimulation (playing quiet sounds during sleep) can normalize brain activity during sleep and improve memory in patients with schizophrenia. The investigators will do this by measuring sleep and memory performance under two conditions separated by one week: receiving auditory stimulation during sleep and not receiving auditory stimulation during sleep. The investigators will study healthy subjects and outpatients with schizophrenia.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
03/18/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Schizophrenia
Register for Updates
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
NCT06041646
Recruiting
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/15/2024
Locations: BioXcel Clinical Research Site, Little Rock, Arkansas +1 locations
Conditions: Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Register for Updates
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
NCT05838625
Recruiting
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Click Therapeutics, New York, New York
Conditions: Schizophrenia
Register for Updates
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
NCT05443724
Recruiting
The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/12/2024
Locations: Phoenix, Arizona, Phoenix, Arizona +79 locations
Conditions: Schizophrenia
Register for Updates
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
NCT05227690
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/12/2024
Locations: Little Rock, Arkansas, Little Rock, Arkansas +24 locations
Conditions: Schizophrenia
Register for Updates
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
NCT05227703
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/12/2024
Locations: Bentonville, Arkansas, Bentonville, Arkansas +26 locations
Conditions: Schizophrenia
Register for Updates
C-Cog in Early Course Schizophrenia Study
NCT05662306
Recruiting
The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Jackson Memorial Hospital, Miami, Florida
Conditions: Schizophrenia
Register for Updates
Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia
NCT05343598
Recruiting
This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study how hallucinations work in schizophrenia. TMS is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. The magnetic field is produced by a coil that is held next to the scalp. In this study the investigators will be stimulating the brain to learn more about how TMS might improve these symptoms of schizophrenia.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
03/11/2024
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Schizophrenia, Schizo Affective Disorder
Register for Updates
Peripheral Immune System in Individuals With Schizophrenia
NCT05109065
Recruiting
The investigators are seeking healthy volunteers and people with schizophrenia or schizoaffective disorder for a clinical study of the immune system in psychotic disorders. This is an observational study, to understand the ways in which the immune system may be contributing to the disease process.
Gender:
All
Ages:
Between 18 years and 40 years
Trial Updated:
03/07/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Register for Updates
Prebiotic Treatment in People With Schizophrenia
NCT05527210
Recruiting
The proposed project is based on the observation that schizophrenia is characterized by a chronic pro-inflammatory state, which contributes to the severity of a number of the clinical manifestations of the illness, including cognitive impairments, the treatment of which represents a critically important unmet therapeutic need.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
03/06/2024
Locations: Maryland Psyciatric Research Center, Catonsville, Maryland
Conditions: Schizophrenia, Schizoaffective Disorder
Register for Updates
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years
NCT06225115
Recruiting
This first-in-human clinical trial with a randomized, double-blind, placebo-controlled, dose-escalation study design is regarded as standard to test the safety, tolerability, and pharmacokinetics of KYN-5356. The study comprises 3 parts: Part 1: Single Ascending Dose study Part 2: Multiple Ascending Dose study Part 3: Food Effect study The aim of Parts 1 and 2 of the study is to evaluate the safety and tolerability following single and multiple ascending doses of KYN-5356. The secondary aim... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
03/05/2024
Locations: Parexel Los Angeles Early Phase Clinical Unit, Glendale, California
Conditions: Cognitive Dysfunction, Schizophrenia
Register for Updates
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04578756
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder (ASD) and to establish the benefit-risk profile of long-term treatment in this population.
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
03/04/2024
Locations: Harmonex Neuroscience Research /ID# 234938, Dothan, Alabama +39 locations
Conditions: Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
Register for Updates